BioXcel Therapeutics (BTAI) Reports Q1 Loss of $1.08/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Join SI Premium – FREE
BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.08), versus ($0.79) reported last year.
For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- CrossAmerica Partners (CAPL) Misses Q3 EPS by 8c
- Personalis, Inc. (PSNL) Misses Q3 EPS by 6c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
